Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland.
Clinical Research Centre, Medical University of Bialystok, M. Sklodowskiej-Curie 24a, 15-276 Bialystok, Poland; Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.
Biochim Biophys Acta Rev Cancer. 2022 May;1877(3):188721. doi: 10.1016/j.bbcan.2022.188721. Epub 2022 Mar 16.
The diagnosis of glioma is mainly based on imaging methods that do not distinguish between stage and subtype prior to histopathological analysis. Patients with gliomas are generally diagnosed in the symptomatic stage of the disease. Additionally, healing scar tissue may be mistakenly identified based on magnetic resonance imaging (MRI) as a false positive tumor recurrence in postoperative patients. Current knowledge of molecular alterations underlying gliomagenesis and identification of tumoral biomarkers allow for their use as discriminators of the state of the organism. Moreover, a multiomics approach provides the greatest spectrum and the ability to track physiological changes and can serve as a minimally invasive method for diagnosing asymptomatic gliomas, preceding surgery and allowing for the initiation of prophylactic treatment. It is important to create a vast biomarker library for adults and pediatric patients due to their metabolic differences. This review focuses on the most promising proteomic, metabolomic and lipidomic glioma biomarkers, their pathways, the interactions, and correlations that can be considered characteristic of tumor grade or specific subtype.
神经胶质瘤的诊断主要基于影像学方法，在进行组织病理学分析之前，这些方法无法区分肿瘤的分期和亚型。神经胶质瘤患者通常在疾病的症状期被诊断出来。此外，术后患者的磁共振成像（MRI）可能会错误地将愈合的瘢痕组织识别为假阳性肿瘤复发。目前对神经胶质瘤发生的分子改变的认识以及肿瘤标志物的鉴定，使得它们可以作为机体状态的鉴别标志物。此外，多组学方法提供了最大的谱和跟踪生理变化的能力，并且可以作为一种微创方法用于诊断无症状的神经胶质瘤，在手术之前进行，并允许开始预防性治疗。由于成人和儿科患者的代谢差异，因此创建一个庞大的生物标志物库非常重要。本综述重点介绍了最有前途的神经胶质瘤蛋白质组学、代谢组学和脂质组学生物标志物及其途径、相互作用和相关性，这些标志物可被认为是肿瘤分级或特定亚型的特征。
